Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient

N. M. Katz, P. F. Pierce, R. A. Anzeck, M. S. Visner, H. G. Canter, M. L. Foegh, D. L. Pearle, C. Tracy, A. Rahman

Research output: Contribution to journalArticlepeer-review

Abstract

Pulmonary aspergillosis developed in a 52-year-old man 2 months after heart transplantation for ischemic cardiomyopathy. Conventional amphotericin B therapy caused marked deterioration of his already compromised kidney function after only 10% of the projected total dose. Conversion to liposomal encapsulated amphotericin B was associated with reversal of the kidney dysfunction and clearing of the pulmonary infiltrate. It is now 16 months since completion of therapy, and there is no evidence of recurrent infection.

Original languageEnglish (US)
Pages (from-to)14-17
Number of pages4
JournalJournal of Heart Transplantation
Volume9
Issue number1
StatePublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient'. Together they form a unique fingerprint.

Cite this